Comparative Diagnostic Value of Serological and Synovial Tests for Periprosthetic Joint Infections: A Comprehensive Analysis

血清学检测和滑液检测在假体周围关节感染诊断中的价值比较:一项综合分析

阅读:3

Abstract

BACKGROUND: Prompt diagnosis of periprosthetic joint infections (PJIs) is crucial for providing optimal care. Currently, there are no gold-standard tests available. An ideal test would be simple to implement, cost-effective, and readily available. We aimed to determine the best single or combined serological or synovial markers for diagnosing PJIs. METHODS: There were 177 of 313 patients who had PJIs between April 2012 and March 2023 and a control group of 60 patients who were included in this retrospective review. The PJIs were diagnosed using Musculoskeletal Infection Society (MSIS) and European Bone and Joint Infection Society (EBJIS) criteria. Serum (C-reactive protein [CRP], white blood-cell [WBC] count, neutrophil-lymphocyte ratio [NLR], polymorphonuclear neutrophil percentage [PMN%]), and synovial fluid (WBC, NLR, PMN%) parameters were compared between the 2 groups. We determined the sensitivity, specificity, area under the curve (AUC), and cutoff values (COV) for each marker. We determined the best combination of markers to diagnose PJIs. There was no statistical significance between the demographic data of the control and treatment groups. RESULTS: The S-CRP had the highest AUC of 0.912 with a COV of 16.15 mg/dL (Sensitivity 79.6%, Specificity 97.8%). The combination of tests, S-CRP, synovial fluid (SF-WBC), and S-NLR demonstrated the highest AUC of 0.946 (Sensitivity 93%, Specificity 90.9%). The COV for SF-WBC was 5.75 cells/μL (AUC 0.803; Sensitivity 70.3%, Specificity 97.1%); S-NLR COV was 3.659 (AUC 0.803; Sensitivity 67.3%, Specificity 88%). CONCLUSION: We found the combination of S-CRP, SF-WBC, and S-NLR to be valuable in diagnosing PJI with high sensitivities and specificities. It can be easily implemented by clinicians without additional cost or equipment. It is important to use this with a thorough clinical and physical examination as well as other modalities (i.e., MSIS/EBJIS criteria). LEVEL OF EVIDENCE: Retrospective Comparative Study-Level III evidence. See Instructions for Authors for a complete description of levels of evidence.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。